"Ribavirin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A nucleoside antimetabolite antiviral agent that blocks nucleic acid synthesis and is used against both RNA and DNA viruses.
| Descriptor ID |
D012254
|
| MeSH Number(s) |
D13.570.800.790
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Ribavirin".
Below are MeSH descriptors whose meaning is more specific than "Ribavirin".
This graph shows the total number of publications written about "Ribavirin" by people in this website by year, and whether "Ribavirin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 0 | 1 | 1 |
| 2005 | 1 | 0 | 1 |
| 2006 | 1 | 0 | 1 |
| 2007 | 1 | 0 | 1 |
| 2008 | 4 | 1 | 5 |
| 2009 | 2 | 0 | 2 |
| 2010 | 1 | 1 | 2 |
| 2011 | 2 | 1 | 3 |
| 2012 | 3 | 1 | 4 |
| 2013 | 1 | 0 | 1 |
| 2014 | 2 | 0 | 2 |
| 2015 | 0 | 3 | 3 |
| 2016 | 1 | 4 | 5 |
To return to the timeline,
click here.
Below are the most recent publications written about "Ribavirin" by people in Profiles.
-
Brief Report: CD14brightCD16- monocytes and sCD14 level negatively associate with CD4-memory T-cell frequency and predict HCV-decline on therapy. J Acquir Immune Defic Syndr. 2016 11 01; 73(3):258-262.
-
Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With?Genotype 1 Hepatitis C Virus Infection in an Open-Label, Phase 2 Trial. Gastroenterology. 2016 11; 151(5):893-901.e1.
-
Ribavirin-Free Regimen With Sofosbuvir and Velpatasvir Is Associated With High Efficacy and Improvement of Patient-Reported Outcomes in Patients With Genotypes 2 and 3 Chronic Hepatitis C: Results From Astral-2 and -3 Clinical Trials. Clin Infect Dis. 2016 10 15; 63(8):1042-1048.
-
Faldaprevir, pegylated interferon, and ribavirin for treatment-na?ve HCV genotype-1: pooled analysis of two phase 3 trials. Ann Hepatol. 2016 May-Jun; 15(3):333-49.
-
Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir With or Without Ribavirin in HCV-Infected Patients Taking Concomitant Acid-Reducing Agents. Am J Gastroenterol. 2016 06; 111(6):845-51.
-
Interferon-free regimens containing setrobuvir for patients with genotype 1 chronic hepatitis C: a randomized, multicenter study. Liver Int. 2016 Apr; 36(4):505-14.
-
Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosis. JAMA. 2015 May 05; 313(17):1736-44.
-
Pegylated interferon based therapy with second-wave direct-acting antivirals in genotype 1 chronic hepatitis C. Liver Int. 2015 Jan; 35 Suppl 1:11-7.
-
Randomized study of danoprevir/ritonavir-based therapy for HCV genotype 1 patients with prior partial or null responses to peginterferon/ribavirin. J Hepatol. 2015 Feb; 62(2):294-302.
-
Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014 Apr 24; 370(17):1604-14.